

A phase I trial of sunitinib, a tyrosine kinase inhibitor combined with ionizing irradiation in rectal cancer: protocol KIRC 08-01

phase I - radiotherapy - rectal cancer - sunitinib - tyrosine kinase inhibitor

The standard treatment for locally advanced rectal cancer combines radiotherapy with surgery and chemotherapy. It has been demonstrated that neoadjuvant radiotherapy provides superior results. The results of this study will be compared with regard to dose delivery to the breast, dose to healthy organs and tissues and cost-efficiency regarding departmental resources. The results of this study will serve for the standardization of breast radiotherapy techniques within the Liège University Hospital.

For more information please contact:

Philippe Coucke

E-mail: pcoucke@chu.ulg.ac.be